메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
저널정보
대한뇌졸중학회 대한뇌졸중학회지 대한뇌졸중학회지 제11권 제2호
발행연도
2009.1
수록면
67 - 72 (6page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
In The Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial, recurrent stroke occurred in 9.0% receiving aspirin and extended-release dipyridamole (ASA-ERDP) and in 8.8% receiving clopidogrel [hazard ratio (HR) 1.01; 95% confidence interval (CI) 0.92 to 1.11]. There were more major hemorrhagic events among ASA-ERDP group (4.1% vs. 3.6%, P<0.05). Therapy with telmisartan did not significantly lower the rate of recurrent stroke, major cardiovascular events, or diabetes in spite of blood pressure (BP) lowering. In The Cilostazol versus Aspirin for Secondary Ischaemic Stroke Prevention (CASISP) trial comparing cilostazol with aspirin in patients with ischemic stroke, cilostazol showed non-significant trend to prevent recurrent stroke (HR 0.62; 95% CI 0.30-1.26). Symptomatic and aymptomatic hemorrhage was less frequent in cilostazol group. Three-year follow-up of The Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy (SAPPHIRE) trial showed that there was no difference between carotid artery stenting group and endarterectomy group. Two to four-year follow-up study of The Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) and Endarterectomy Versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis (EVA-3S) trial, in which patients with symptomatic carotid stenosis were included, also showed no difference of cardiovascular events including stroke. These results suggested that mid or long-term outcome is comparable between stenting and endarterectomy. Meta-analysis from 8,832 patients with statin therapy showed decreased incidence of recurrent ischemic stroke [relative risk (RR) 0.80; 95% CI 0.70-0.92], while increased risk of hemorrhagic stroke (RR 1.73; 95% CI 1.19-2.50) in statin group. Post-hoc analysis of Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study revealed that hemorrhagic stroke as an entry event, age, hypertension, ator-vastatin per se, and small vessel disease subtype increase the risk of intracerebral hemorrhage. (Korean J Stroke 2009;11:67-72)

목차

등록된 정보가 없습니다.

참고문헌 (15)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0